- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development planned

Related Keywords

Canada , United Kingdom , Colombo , Western , Sri Lanka , Texas , United States , Philadelphia , Pennsylvania , Emaase , Schleswig Holstein , Germany , France , Kathleen Moore , David Hong , Adrian Rawcliffe , Julip Miller , Dana Lynch , Investigator Council , Nasdaq , National Cancer Institute Surveillance , End Results Program , Stephenson Cancer Center , University Of Oklahoma , International Agency For Research On Cancer , Department Of Investigational Cancer Therapeutics , University Of Texas Md Anderson Cancer Center , Division Of Gynecologic Oncology , Exchange Commission , Corporate Communications , Foundation Inc , European Society For Medical Oncology , Corporate Affairs , United Newsfile Corp , Objective Response Rate , European Society , Medical Oncology , Chief Executive Officer , Deputy Chair , Investigational Cancer Therapeutics , Cell Associated Neurotoxicity Syndrome , Deputy Chairman , Cancer Center , Live Virtual Event Today , Gynecologic Oncology , Associate Director , Specific Peptide Enhanced Affinity Receptor , Private Securities Litigation Reform Act , Adaptimmune Annual Report , Quarterly Reports , Current Reports , Senior Director , Best Overall Response , Evaluable Patients , Response Characteristics , High Unmet Medical Needs , Solid Tumor , Neck Cancers , Cancer Observatory , International Agency , Cancer Institute Surveillance , Cancer Stat Facts , Clin Oncol , Adaptimmune , Herapeutics , Eports , Ositive , Ata , Urpass , Rial , Utlines , Lans , Dvanced , Linical , Evelopment , Ultiple , Age , Olid , Umors ,